Safety committee recommends continuation of Atossa's Ph I endoxifen trial

Atossa Genetics Inc. (NASDAQ:ATOS) said an independent safety committee recommended continuation to the next dosing level in a Phase I trial of breast cancer candidate endoxifen. The recommendation comes after the committee reviewed data from the first cohort of the double-blind, placebo-controlled, Australian trial. The trial, which Atossa began in March, is evaluating safety and pharmacokinetics of ascending doses of oral and topical endoxifen in 48 healthy women...